Fund Holdings — Sarissa Capital Management LP

Total Portfolio Value:
$571.63M
Total Bought:
$27.77M
Total Sold:
$14.15M
Net Transaction:
+$13.62M
Securities
▲▼
SharesValue
Q4 2023
▲▼
Q1 2024
▲▼
Change
▲▼
Q4 2023
▲▼
Q1 2024
▲▼
Weight (%)
▲▼
Change
▲▼
Ironwood Pharmaceuticals, Inc.CL A(IRWD)16,390,00016,390,0000$187.50M$142.76M24.97%-$44.74M
Biogen Inc.(BIIB)643,000643,0000$166.39M$138.65M24.26%-$27.74M
Innoviva, Inc.(INVA)7,277,0007,277,0000$116.72M$110.90M19.40%-$5.82M
Gilead Sciences, Inc.(GILD)1,075,4001,103,282+27,882$87.12M$80.82M14.14%-$6.30M
Neurocrine Biosciences, Inc.(NBIX)470,000346,426-123,574$61.93M$47.78M8.36%-$14.15M
Amarin Corp PlcADR24,850,62324,850,6230$21.62M$22.14M3.87%+$516.9K
Cytokinetics, Incorporated(CYTK)0300,000+300,000$0$21.03M3.68%+$21.03M
BioCryst Pharmaceuticals, Inc.(BCRX)1,000,0001,094,168+94,168$5.99M$5.56M0.97%-$431.6K
Vor Biopharma Inc.(VOR)618,000618,0000$1.39M$1.46M0.26%+$74.2K
Regulus Therapeutics Inc185,183185,1830$237.0K$533.3K0.09%+$296.3K
Page 1 of 1
Sarissa Capital Management LP — 13F Holdings — Q1 2024 | TickerTrail